Philip Verghese

Dr. Verghese serves as the Vice President, Translational Sciences and Operations at C₂N. In this role, he leads several facets of discovery stage portfolio, analytical and clinical validations, operations, and commercialization of C₂N products. Dr. Verghese is a protein and lipid biochemist with in-depth experience in basic and translational neurosciences of Alzheimer’s disease and related dementia. His work on crucial proteins associated in neurodegeneration, especially apolipoprotein E (ApoE) and ApoE receptors have been published in high impact journals and added new perspectives in the field of neurodegeneration. He has authored/co-authored approximately 30 peer reviewed scientific articles exploring basic and disease related mechanisms and biomarker and drug development. Prior to this position, Dr. Verghese was a Principal Scientist at C₂N, where he assumed key roles in preclinical and clinical activities, IND filings, creation of translational biomarker strategies and due diligence for licensing activities associated with therapeutic candidates in Alzheimer’s Disease and other neurodegenerative diseases. Prior to Joining C₂N, Dr. Verghese conducted his post-doctoral fellowship in the laboratory of Dr. David Holtzman, Washington University School of Medicine in Saint Louis, under the BrightFocus foundation postdoctoral research fellowship. He received his BSc in chemistry and MSc in Biochemistry from University of Pune, India. He obtained his PhD in Biochemistry from OSU, Stillwater and a Graduate Diploma in Business Studies from DBS, Dublin, Ireland.